The prognostic effect of pretreatment 18F-FDG PET/CT metabolic parameters in locally advanced Esophageal Squamous Cell Carcinoma treated with definitive chemoradiotherapy

被引:6
作者
Sakin, Abdullah [1 ]
Ozcelik, Mahsun [2 ]
Sahin, Suleyman [3 ]
Aydemir, Ozan [4 ]
Aldemir, Mehmet Naci [4 ]
Iliklerden, Umit Haluk [5 ]
Kotan, Mehmet Cetin [5 ]
机构
[1] Medipol Univ, Medipol Bahcelievler Hosp, Dept Med Oncol, TR-34384 Istanbul, Turkey
[2] Yuzuncu Yil Univ, Dept Nucl Med, Med Sch, TR-65030 Van, Turkey
[3] Van Res & Training Hosp, Dept Med Oncol, Van, Turkey
[4] Yuzuncu Yil Univ, Dept Med Oncol, Med Sch, TR-65030 Van, Turkey
[5] Yuzuncu Yil Univ, Dept Gen Surg, Med Sch, Van, Turkey
来源
SURGICAL ONCOLOGY-OXFORD | 2022年 / 43卷
关键词
Metabolic tumor volume; Tumor lesion glycolysis; Esophageal cancer; Chemoradiotherapy; Squamous cell carcinoma; POSITRON-EMISSION-TOMOGRAPHY; TOTAL LESION GLYCOLYSIS; TUMOR VOLUME; F-18-FDG PET/CT; CANCER; CHEMORADIATION; SURGERY; ADENOCARCINOMA; CHEMOTHERAPY; RADIOTHERAPY;
D O I
10.1016/j.suronc.2022.101809
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: In this study, we aimed to examine the relation between pre-treatment 18F-FDG PET/CT metabolic parameters [(including the maximum standard uptake value (SUVmax), metabolic tumor volume (MTV), and tumor lesion glycolysis (TLG)] and treatment response and survival in locally-advanced Esophageal Squamous Cell Cancer (ESCC) treated with definitive chemoradiotherapy (dCRT). Methods: A total 76 patients with locally-advanced ESCC who received dCRT between June 2015 and December 2019 were included in this retrospective study. Patients were divided into two groups as complete response (CR) or non-complete response (Non-CR) according to response to treatment. AUC was obtained as 0.749 (p < 0.001) in the ROC curve drawn by MTV for the CR. The MTV value was <= 12 cm(3), with 72.1% sensitivity and 73.0% specificity. Results: Of the 76 patients, 38 (50%) were male and 38 (50%) were female. The median age was 62 (39-84) years. The treatment response in 35 (46%) patients was CR. MTV value was > 12cm3 in 41(54%) patients. Median follow-up time was 14.5 months. In patients with MTV > 12cm3, median progression-free survival(mPFS) and median overall survival(mOS) were 9 months and 11 months, respectively, whereas mPFS and OS could not be reached in those with MTV & LE;12 cm3 (p < 0.001 and p < 0.001, respectively). In patients with non-CR, mPFS and mOS were 8 months and 9 months, respectively, whereas mPFS and OS could not be reached in patients with CR (p < 0.001 and p < 0.001, respectively). In multivariate analysis, age (odds ratio [OR], 1.07), ECOG PS (OR, 11.1), and MTV (OR, 4.73) were found to be the factors affecting treatment response. Conclusion: In our study, treatment response and MTV were found to be the factors associated with survival in patients treated with dCRT, showing the pre-treatment MTV value as a predictor of treatment response.
引用
收藏
页数:6
相关论文
共 35 条
[1]   Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: An intergroup study [J].
AlSarraf, M ;
Martz, K ;
Herskovic, A ;
Leichman, L ;
Brindle, JS ;
Vaitkevicius, VK ;
Cooper, J ;
Byhardt, R ;
Davis, L ;
Emami, B .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (01) :277-284
[2]  
Baquet Claudia R, 2005, J Natl Med Assoc, V97, P1471
[3]  
Bedenne L, 2007, J CLIN ONCOL, V25, P1160, DOI 10.1200/JCO.2005.04.7118
[4]   FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0 [J].
Boellaard, Ronald ;
Delgado-Bolton, Roberto ;
Oyen, Wim J. G. ;
Giammarile, Francesco ;
Tatsch, Klaus ;
Eschner, Wolfgang ;
Verzijlbergen, Fred J. ;
Barrington, Sally F. ;
Pike, Lucy C. ;
Weber, Wolfgang A. ;
Stroobants, Sigrid ;
Delbeke, Dominique ;
Donohoe, Kevin J. ;
Holbrook, Scott ;
Graham, Michael M. ;
Testanera, Giorgio ;
Hoekstra, Otto S. ;
Zijlstra, Josee ;
Visser, Eric ;
Hoekstra, Corneline J. ;
Pruim, Jan ;
Willemsen, Antoon ;
Arends, Bertjan ;
Kotzerke, Joerg ;
Bockisch, Andreas ;
Beyer, Thomas ;
Chiti, Arturo ;
Krause, Bernd J. .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 (02) :328-354
[5]   Correlation Between Tumor Regression Grade and Clinicopathological Parameters in Patients With Squamous Cell Carcinoma of the Esophagus Who Received Neoadjuvant Chemoradiotherapy [J].
Chao, Yin-Kai ;
Chang, Chun-Bi ;
Chuang, Wen-Yu ;
Wen, Yu-Wen ;
Chang, Hsien-Kun ;
Tseng, Chen-Kan ;
Yeh, Chi-Ju ;
Liu, Yun-Hen .
MEDICINE, 2015, 94 (34) :e1407
[6]   Phase III trial of protracted compared with split-course chemoradiation for Esophageal carcinoma: Federation Francophone de Cancerologie Digestive 9102 [J].
Crehange, Gilles ;
Maingon, Philippe ;
Peignaux, Karine ;
N'guyen, Tan Dat ;
Mirabel, Xavier ;
Marchal, Christian ;
Verrelle, Pierre ;
Roullet, Bernard ;
Bonnetain, Franck ;
Bedenne, Laurent .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (31) :4895-4901
[7]   Analyzing oropharyngeal cancer survival outcomes: a decision tree approach [J].
de Felice, Francesca ;
Humbert-Vidan, Laia ;
Lei, Mary ;
King, Andrew ;
Urbano, Teresa Guerrero .
BRITISH JOURNAL OF RADIOLOGY, 2020, 93 (1111)
[8]   Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma [J].
Flamen, P ;
Lerut, A ;
Van Cutsem, E ;
De Wever, W ;
Peeters, M ;
Stroobants, S ;
Dupont, P ;
Bormans, G ;
Hiele, M ;
De Leyn, P ;
Van Raemdonck, D ;
Coosemans, W ;
Ectors, N ;
Haustermans, K ;
Mortelmans, L .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (18) :3202-3210
[9]   Positron Emission Tomography (PET) in Oncology [J].
Gallamini, Andrea ;
Zwarthoed, Colette ;
Borra, Anna .
CANCERS, 2014, 6 (04) :1821-1889
[10]   Prognostic Value of Volumetric Parameters of Pretreatment 18F-FDG PET/CT in Esophageal Cancer: A Systematic Review and Meta-analysis [J].
Han, Sangwon ;
Kim, Yeon Joo ;
Woo, Sungmin ;
Suh, Chong Hyun ;
Lee, Jong Jin .
CLINICAL NUCLEAR MEDICINE, 2018, 43 (12) :887-894